[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 8.125 0.00 08:00:00
Bid Price Offer Price High Price Low Price Open Price
7.75 8.50 8.125 8.125 8.125
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.37 -2.55 -0.66 31
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 8.125 GBX

Eden Research (EDEN) Latest News

More Eden Research News
Eden Research Investors    Eden Research Takeover Rumours

Eden Research (EDEN) Discussions and Chat

Eden Research Forums and Chat

Date Time Title Posts
25/10/202117:27Eden Research10,880
28/9/202112:47Eden Research; novel encapsulation and delivery technologies1,105
07/1/202118:37Eden....Onward and Upwards!-
07/3/201713:47Eden Research- The Natural Solution172
27/2/201611:20Eden Research- The Natural Solution3

Add a New Thread

Eden Research (EDEN) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Eden Research trades in real-time

Eden Research (EDEN) Top Chat Posts

DateSubject
25/10/2021
09:20
Eden Research Daily Update: Eden Research Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 8.13p.
Eden Research Plc has a 4 week average price of 7.63p and a 12 week average price of 7.63p.
The 1 year high share price is 20.50p while the 1 year low share price is currently 7.25p.
There are currently 380,340,229 shares in issue and the average daily traded volume is 125,535 shares. The market capitalisation of Eden Research Plc is £30,902,643.61.
14/10/2021
16:51
erinvale1: Investing: Eden is very good at fine words, but less so at delivering sales. Perhaps to repeat myself, we have had 'significant' agreements in the past, none of which have generated sales. A few examples from Eden's annual reports and correspondence below. Is anyone surprised that markets no longer take Eden seriously. October 2004 Eden announced that heads of agreement have been agreed with Thallo Eco Products Corporation to distribute the nematode treatment product extensively in the US with minimum royalties of US$15m over 10 years. Outcome: No payments forthcoming. Eden announced that significant sales would deliver in 2005/06. Outcome: Turnover 2005 zero; 2006 102,559! Jan 2006 Eden announced that the first product to be marketed under the Redestos agreement will be Eden’s encapsulated fungicidal product for treating botrytis, with anticipated revenues starting in 2007. Outcome: no marketing, Eden mired in EU approval process and regulation. May 2006: personal letter: 'obtaining approval for use of 3AEY in this major market (USA) within two years maximum". Outcome: 2021 - still no US approval - unless I have missed something. May 2006: (same letter): ' We do expect the product to soon be available in most major wine growing regions. Outcome: 2021 - sales minimal. August 2007: 'concluded a major manufacturing and distribution agreement for Western Europe and the USA with Cheminova....this compliments the comapny's existing partnerships with Redestos SA in Greece and the Balkans, Zagro PTE in SE Asic and Xeda Intl in the post harvest sector. Cheminova is likely to start selling in Italy and Spain, then moving into France and Germany. Initial sales are likely to be small in 2008, with a full sales programme in 2009. Outome: non delivery. Sales still non-existent in 2012/2013 - £44k & £80k respectively.
01/10/2021
20:04
neutralpov: spadeychops 1 Oct '21 - 16:46 - 10712 > when EDEN share price climbs upto and past 20p and well beyond Errrr, except that the share price has just been there to (just) beyond 20p in a carefully contrived ramp 'n pump which allowed those "in the know", mates of optionholders too, to dump and exit leaving complete fools like you holding. Came crashing down to 8p. :D Or didn't you notice, bungapoop?
01/10/2021
16:46
spadeychops: Likewise, when EDEN share price climbs upto and past 20p and well beyond, will you fade away. Of course you will.
30/9/2021
12:45
spadeychops: The rise and fall of the share price has been because ot the expectations around corteva and then the reveal of the 2024 timeline Th green index award was not announced or for warned it was coming. The FRC investigation was explained and materially fairly insignificant. However; important it was, but again the effect it had on share price at the time was barely noticeable. Look at the timeline of events and the share price If you are so negative on EDEN why are you hear this is what I fail to understand…I’m here because I’m invested and believe they’ll come good. You just post negativity on something I presume you don’t own?
26/9/2021
10:42
erinvale1: The Corteva deal may well deliver results in 3-5 years, as per RNS. Reviewing Eden's track record, the floor is littered with 'transformative' deals and promises which have failed to deliver. Some examples: October 2004 Eden announced that heads of agreement have been agreed with Thallo Eco Products Corporation to distribute the nematode treatment product extensively in the US with minimum royalties of US$15m over 10 years. Outcome: No payments forthcoming. Eden announced that significant sales would deliver in 2005/06. Outcome: Turnover 2005 zero; 2006 102,559!  Jan 2006 Eden announced that the first product to be marketed under the Redestos agreement will be Eden’s encapsulated fungicidal product for treating botrytis, with anticipated revenues starting in 2007. Outcome: no marketing, Eden mired in EU approval process and regulation.  May 2006: personal letter: 'obtaining approval for use of  3AEY in this major market (USA) within two years maximum". Outcome: 2021 - still no US approval.  May 2006: (same letter): ' We do expect the product to soon be available in most major wine growing regions. Outcome: 2021 - sales minimal. August 2007: 'concluded a major manufacturing and distribution agreement for Western Europe and the USA with Cheminova....this compliments the comapny's existing partnerships with Redestos SA in Greece and the Balkans, Zagro PTE in SE Asic and Xeda Intl in the post harvest sector. Cheminova is likely to start selling in Italy and Spain, then moving into France and Germany. Initial sales are likely to be small in 2008, with a full sales programme in 2009. Outome: non delivery. Sales still non-existent in 2012/2013 - £44k & £80k respectively.
09/9/2021
12:22
erinvale1: Weywey - it is a disgrace that, after so many years, Eden's technology remains unknown among Europe's top winemakers. Were the company competently run, personal letters would have been sent to all significant European wineries, offering them a discounted - free for the very top estates - trial package of Mevalone. This would be far more cost effective than listings on agri-pharmas or funding an in-house laboratory. This would help establish a lasting, personal, relationship between the company and winery decision makers and a direct line of sales. Botrytis, grey rot, fungal infection and nematodes are perennial issues for grape growers. This matters when your income depends on rot-free fruit. Once the top people saw that Mevalone / Cedroz worked, word would spread rapidly. That's a credible marketing strategy. Instead, Eden prefers corporatism: useless, costly, consultants - head of biology development etc - and non-performing distribution agreements.It loves to tell us how wonderful it is via expensive, glossy presentations. Its 2020 annual report runs to 106 pages, full of worthless puffery - on sales of £1.1m!! Sean Smith has been in post for 5+ years, during which time he has been paid handsomely. In 2020 he and the CFO were paid a total of £618k plus the grant of generous options. This represents 56.85% of the company's sales. Eden is poorly managed by a less than stellar CEO and CFO. Its share price has been in decline for months. On its present trajectory, the company is unlikely to survive much longer. If anyone here can see what might turn the share price round, please post!
08/9/2021
18:13
timbo_slice: Neuts I'm still happy to meet you for a beer if you like? I'm holding Eden it was clearly an error but what else can I do at this time.. I would hate to think of the market makers taking advantage of a poor PI like me. So I won't sell and I will try and make enough money elsewhere to cover my losses... Yes I agree Erin that the salaries that the Directors are paid are extortionate and not in line with the share price or performance of Eden to date. My expectations are zero and as I've said before on here I'll wait for the next cycle of news (whether real or spin) and make a decision at that time... the gullible part of me still wants to believe just like I want to believe you Neuts are only on this board out of the goodness of your heart. As for divorce and suicide its a tragic waste of life and anyone who feels suicidal can DM me. I dont have £20m to indemnify anyone's losses but its always better to talk and to reach out to someone. I still expect Eden to raise money at some point. And that's always a good point to average in like the mug punter I sometimes am.
31/7/2021
11:07
attyg: Some expressions by posters that the bounce may be from a leak of an RNS on Monday. My thoughts are that an RNS is unlikely,(delighted to be proved wrong). In my view,the bounce is more to do with the realisation that Eden is incredibly cheap. I expect the share price to be £2 within a few years. Why? The nomad has allowed Eden to state and re-state again how the Corteva deal will bring in a minimum of €40m in revenues. Let's make it simple, £40m sales, £20m GP drops to the bottom line, PE of 40 (very strong upward trajectory in profit) gives a share price of £2. Cenkos have stated the GP% typically north of 40%; Eden have stated likely upside on revenues. Must be some form of minimum sales level in the agreement for the nomad to allow. Corteva RNS all over the place with timing of revenues - possible commercial launch for 2024 growing season, could be delays if regulatory approval held up - but also ASAP! per slide 19 in the AGM presentation. Readers can form their own view on the likelihood of such a scenario coming to pass, but there it is, an agreement with a global major with a minimum revenue of €40m. NOMADs certainly do not allow such matters to be stated if they are not set in concrete.
28/7/2021
18:57
erinvale1: Corteva RNS - share price plummets. CEO buys shares. share price plummets. Says it all about the market‘s view of Eden.
22/7/2021
17:39
investingisatrickygame: Post 10218 Very interesting post attyG Hopefully Eden share price will begin to take care of itself on a a few new and due announcements. "This'll get NeutralPOV going. A company called Dechra Pharmaceuticals with a pre tax profit of almost £41m for the year to 30 June 2020 is trading on a PE of 146. So every prospect of Eden generating a PTP of £40m in the not too distant. A PE of 146 on £40m PTP would give us a share price of 56. That of course is pounds not pence. Reading Spadeychops postings (keep 'em up spadey) I gather Neutral will be bathing in champagne pretty soon with his £19 million investment in Eden."
Eden Research share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
EDEN
Eden Resea..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211025 18:17:04